| Primary information |
|---|
| OV_ID | OV_4489 |
| Virus Name | Herpes simplex virus |
| Strain | RH2 |
| Virus type | DNA |
| Virus family | Herpesviridae |
| Modification in virus genome | Mutant for Gamma 34.5 gene and gB gene |
| Virus alone | Yes |
| Virus in combination iwth drug/radiation | No |
| Immune gene induction in virus genome | No |
| Source of cell line | NA |
| Origin of cell line | NA |
| Cell line | NA |
| Concentration of cell line | 0 |
| In-vitro toxicity | NA |
| Assay | NA |
| In-vitro virus concentration | NA |
| In-vitro result | NA |
| Model organism | C3H mice subcutaneous implanted for SCCVII (1 × 10â¶) |
| In-vivo virus concentration | 50 microliter of RH2 virus, 3 times at interval of 2 days |
| In-vivo toxicity | NA |
| In-vivo result | Tumor volume was less than 1587 cubic mm in treated mice compared to control 2996 cubic mm after 25 days |
| Mode of delivery | Intratumoral |
| Pathway induction | Virus induced apoptosis |
| Immunogenic effect | Increased extracellular ATP and HMGB1, indicating immunogenic cell death |
| Clinical trial | NA |
| PMID | 26987291 |